<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03274323</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00146334</org_study_id>
    <nct_id>NCT03274323</nct_id>
  </id_info>
  <brief_title>Trabeculectomy Versus 2-iStent and Prostaglandin Study</brief_title>
  <acronym>TIPS</acronym>
  <official_title>Trabeculectomy Versus 2-iStent and Prostaglandin Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators hypothesize that the synergistic action of iStent in increasing aqueous outflow
      through the trabecular meshwork and use of prostaglandin analog such as travoprost or
      latanoprost to increase uveoscleral outflow will achieve good Intra-ocular Pressure (IOP)
      control with minimal complications in Primary Open Angle Glaucoma (POAG) patients with
      suboptimal IOP on 2 or more medications compared to mitomycin C (MMC) augmented
      trabeculectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective randomized controlled study.

      20 phakic or pseudophakic open angle glaucoma patients with an IOP in the range of 18-30 mmHg
      on 2 or more topical glaucoma medications will be randomly selected to undergo either (1)
      mitomycin-augmented trabeculectomy or (2) placement of 2 iStent devices and initiation of a
      daily prostaglandin analog. This study is looking at the combined effects of the 2 iStents
      and a prostaglandin analog as a method to achieve low IOP. At 3 months (+/- 2 weeks)
      postoperatively, the iStent patients will be left only on the prostaglandin analog with a
      washout performed for any other hypotensive medication used. Patients who had a
      trabeculectomy will be have a terminal washout of all IOP-lowering medications at 3 months
      (+/- 2 weeks) post-surgery. The IOP will then be measured for both groups at 4 months (+/- 3
      weeks) postoperatively.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Difficulty obtaining IDE by the FDA. Currently not worthwhile to pursue further.
  </why_stopped>
  <start_date type="Actual">January 12, 2018</start_date>
  <completion_date type="Actual">January 12, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IOP &lt;= 18 mmHg</measure>
    <time_frame>Post surgery month 4</time_frame>
    <description>IOP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IOP &lt;= 15 mmHg</measure>
    <time_frame>Post surgery month 4</time_frame>
    <description>IOP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IOP &gt;= 20% reduction from untreated baseline</measure>
    <time_frame>Post surgery month 4</time_frame>
    <description>IOP</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>2 iStent with travoprost or latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 iStents will be injected into the trabecular meshwork and patients will be administered topical latanoprost or travoprost following surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>trabeculectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard trabeculectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iStent and travoprost or latanoprost</intervention_name>
    <description>2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure</description>
    <arm_group_label>2 iStent with travoprost or latanoprost</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy</intervention_name>
    <description>Standard trabeculectomy</description>
    <arm_group_label>trabeculectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have mental capacity to give consent

          -  Age &gt;= 21 years

          -  Pseudophakic or phakic without visually significant cataract

          -  Open angle glaucoma

          -  IOP in the range of 18-30 mmHg with 2 or more topical medications

          -  Cup-disc ratio =&lt; 0.9

          -  Best corrected visual acuity of 20/100 or better

        Exclusion Criteria:

          -  Inability to give consent

          -  Inability to tolerate or presence of allergy to prostaglandin analogs

          -  Patient preference for non-surgical treatment or preference for either of the
             recommended surgical modalities in the study

          -  Age &lt; 21 years

          -  Visually significant cataract that would benefit from cataract surgery, as determined
             by the treating surgeon in consultation with the patient

          -  Secondary glaucoma or angle closure glaucoma

          -  Aphakia

          -  Prior glaucoma incisional surgery (trabeculectomy, tube surgery, other Microinvasive
             Glaucoma Surgery (MIGS) surgeries, deep sclerectomy)

          -  Prior laser trabeculoplasty &lt; 90 days prior to screening or absolute failure of prior
             laser trabeculoplasty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2017</study_first_submitted>
  <study_first_submitted_qc>September 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2017</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

